Treatment with Opdivo (nivolumab) after surgery significantly delays disease recurrence or death in patients with muscle-invasive urothelial carcinoma, a form of bladder cancer that has spread to nearby muscles, according to data from a Phase 3 clinical trial. These beneficial effects were seen in the overall population of patients in the CheckMate-274 trial (NCT02632409), as well as in a subgroup whose tumors contained at least 1% of PD-L1 protein. CheckMate-274 is the first Phase 3 trial…
You must be logged in to read/download the full post.
The post Opdivo Effective as Bladder Cancer Post-surgery Therapy, Data Show appeared first on BioNewsFeeds.